Conference Track

Advances in HBV Treatment: 2007

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

HBV Patients Treated With Lamivudine and Experiencing a Suboptimal Response Benefit More From a Switch to Telbivudine Than Continued Lamivudine Treatment
Entecavir Associated With Greater HBV DNA Reduction vs Adefovir at Year 1 in Treatment-Naive HBeAg-Positive Chronic Hepatitis B Patients
FibroScan Identified High Incidence of Fibrosis, Correlated With Biochemical Liver Disease Measures, in Large Chronic HBV–Infected Population
9-Year Follow-up of Long-term Lamivudine Therapy in CHB Patients Demonstrates Full Viral Suppression During First Year Predictive of Overall Treatment Response
Long-term Study of HBeAg-Positive Italian Patients With Chronic Hepatitis B Reveals Prognostic Factors for Mortality
GLOBE Study: Add or Switch to Adefovir a Viable Salvage Option for Telbivudine-Treated Patients Exhibiting Virologic Breakthrough
Long-term Lamivudine Therapy With or Without Adefovir Improves Outcome of Esophageal Varices in HBeAg-Negative Patients With Cirrhosis
HBeAg Response Sustained in Most Patients Treated With Telbivudine or Lamivudine in GLOBE Trial
Entecavir Maintains High Genetic Barrier to Resistance Over 4 Years of Treatment in Nucleoside-Naive Patients
High Rates of Sustained Virologic Response in HBeAg-Negative Chronic Hepatitis B Patients 3 Years Posttreatment With Peginterferon alfa-2a ± Lamivudine
Week 24 Interim Analysis During Treatment Shows Greater HBV DNA Suppression With Peginterferon alfa-2a Plus Adefovir vs Peginterferon alfa-2a Alone in HBV Patients
No Long-term Benefit of Overlapping Lamivudine and Adefovir Prior to Adefovir Monotherapy in Korean Patients With Lamivudine-Resistant HBV
Nucleos(t)ide Analogue Resistance Pathways and Secondary Compensatory Mutations Identified in Chronic Hepatitis B
Modeling Based on Clinical and Laboratory Values Successful in Predicting Mild Fibrosis in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Patients
Phase III Data Suggest That Chronic Hepatitis B Patients Can Still Have Significant Liver Disease Despite ALT < 2 x ULN

Expert Analysis

Advances in HBV Treatment: 2007

Faculty:
Adrian M. Di Bisceglie, MD, FACP Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount clinical data on long-term therapy for the treatment of chronic hepatitis B
Summarize data regarding management strategies for patients with hepatitis B virus treatment–related resistance
Discuss the use of noninvasive methods and models for assessing stage and rate of progression of liver disease

CME CREDIT INFORMATION

Release Date: 06/27/07

Expiration Date: 06/26/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.